Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

NCT04204616 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT04204616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04204616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 11, 2021
Completion date
October 26, 2026
Enrollment
500 (estimated)
Sites
164

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis